Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model

Hao Wu, Di Wen, Ram I. Mahato

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Human islet transplantation can be a permanent treatment of type 1 diabetes if the immune rejection and primary nonfunction (PNF) of transplanted islet grafts were properly addressed. In this study, we determined whether cotransplantation of human bone marrow-derived mesenchymal stem cells (hBMSCs) could prevent immune rejection and improve human islet transplantation in a humanized NOD scid gamma (NSG) mouse model. Human immunity was rebuilt and maintained in NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice up to 13 weeks after intraperitoneal injection of mature human peripheral blood mononuclear cells (PBMCs). The blood glucose control and the levels of serum insulin and c-peptide clearly indicated a better outcome of islet transplantation when islets were cotransplanted with hBMSCs. hBMSCs actively interacted with interleukin-10 (IL-10)-producing CD14 + monocytes to suppress the proliferation and activation of T cells in the PBMC/hBMSC coculture and prevent the T cell recruitment into the transplantation site. hBMSCs also increased the percentage of immunosuppressive regulatory T cells (Tregs) and prevented the cytokine-induced loss-of-function of human islets. Taken together, our studies demonstrated that transplantation of islets with hBMSCs is a promising strategy to improve the outcome of human islet transplantation.

Original languageEnglish (US)
Pages (from-to)1778-1786
Number of pages9
JournalMolecular Therapy
Volume21
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Islets of Langerhans Transplantation
Mesenchymal Stromal Cells
Bone Marrow
Blood Cells
T-Lymphocytes
Regulatory T-Lymphocytes
Immunosuppressive Agents
Coculture Techniques
Intraperitoneal Injections
Type 1 Diabetes Mellitus
Interleukin-10
Blood Glucose
Monocytes
Immunity
Transplantation

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model. / Wu, Hao; Wen, Di; Mahato, Ram I.

In: Molecular Therapy, Vol. 21, No. 9, 09.2013, p. 1778-1786.

Research output: Contribution to journalArticle

@article{55356fdd35c94be791c4d83b406d1bb4,
title = "Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model",
abstract = "Human islet transplantation can be a permanent treatment of type 1 diabetes if the immune rejection and primary nonfunction (PNF) of transplanted islet grafts were properly addressed. In this study, we determined whether cotransplantation of human bone marrow-derived mesenchymal stem cells (hBMSCs) could prevent immune rejection and improve human islet transplantation in a humanized NOD scid gamma (NSG) mouse model. Human immunity was rebuilt and maintained in NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice up to 13 weeks after intraperitoneal injection of mature human peripheral blood mononuclear cells (PBMCs). The blood glucose control and the levels of serum insulin and c-peptide clearly indicated a better outcome of islet transplantation when islets were cotransplanted with hBMSCs. hBMSCs actively interacted with interleukin-10 (IL-10)-producing CD14 + monocytes to suppress the proliferation and activation of T cells in the PBMC/hBMSC coculture and prevent the T cell recruitment into the transplantation site. hBMSCs also increased the percentage of immunosuppressive regulatory T cells (Tregs) and prevented the cytokine-induced loss-of-function of human islets. Taken together, our studies demonstrated that transplantation of islets with hBMSCs is a promising strategy to improve the outcome of human islet transplantation.",
author = "Hao Wu and Di Wen and Mahato, {Ram I.}",
year = "2013",
month = "9",
doi = "10.1038/mt.2013.147",
language = "English (US)",
volume = "21",
pages = "1778--1786",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model

AU - Wu, Hao

AU - Wen, Di

AU - Mahato, Ram I.

PY - 2013/9

Y1 - 2013/9

N2 - Human islet transplantation can be a permanent treatment of type 1 diabetes if the immune rejection and primary nonfunction (PNF) of transplanted islet grafts were properly addressed. In this study, we determined whether cotransplantation of human bone marrow-derived mesenchymal stem cells (hBMSCs) could prevent immune rejection and improve human islet transplantation in a humanized NOD scid gamma (NSG) mouse model. Human immunity was rebuilt and maintained in NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice up to 13 weeks after intraperitoneal injection of mature human peripheral blood mononuclear cells (PBMCs). The blood glucose control and the levels of serum insulin and c-peptide clearly indicated a better outcome of islet transplantation when islets were cotransplanted with hBMSCs. hBMSCs actively interacted with interleukin-10 (IL-10)-producing CD14 + monocytes to suppress the proliferation and activation of T cells in the PBMC/hBMSC coculture and prevent the T cell recruitment into the transplantation site. hBMSCs also increased the percentage of immunosuppressive regulatory T cells (Tregs) and prevented the cytokine-induced loss-of-function of human islets. Taken together, our studies demonstrated that transplantation of islets with hBMSCs is a promising strategy to improve the outcome of human islet transplantation.

AB - Human islet transplantation can be a permanent treatment of type 1 diabetes if the immune rejection and primary nonfunction (PNF) of transplanted islet grafts were properly addressed. In this study, we determined whether cotransplantation of human bone marrow-derived mesenchymal stem cells (hBMSCs) could prevent immune rejection and improve human islet transplantation in a humanized NOD scid gamma (NSG) mouse model. Human immunity was rebuilt and maintained in NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice up to 13 weeks after intraperitoneal injection of mature human peripheral blood mononuclear cells (PBMCs). The blood glucose control and the levels of serum insulin and c-peptide clearly indicated a better outcome of islet transplantation when islets were cotransplanted with hBMSCs. hBMSCs actively interacted with interleukin-10 (IL-10)-producing CD14 + monocytes to suppress the proliferation and activation of T cells in the PBMC/hBMSC coculture and prevent the T cell recruitment into the transplantation site. hBMSCs also increased the percentage of immunosuppressive regulatory T cells (Tregs) and prevented the cytokine-induced loss-of-function of human islets. Taken together, our studies demonstrated that transplantation of islets with hBMSCs is a promising strategy to improve the outcome of human islet transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84883741798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883741798&partnerID=8YFLogxK

U2 - 10.1038/mt.2013.147

DO - 10.1038/mt.2013.147

M3 - Article

C2 - 23765442

AN - SCOPUS:84883741798

VL - 21

SP - 1778

EP - 1786

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 9

ER -